{
  "trial_id": "NCT00734149",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "histologically confirmed multiple myeloma",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "major criteria and one minor criterion or at least three minor criteria",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "plasmacytoma on tissue biopsy",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "marrow plasmacytosis 10-29%",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "monoclonal protein present, less than major criteria",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "lytic bone lesions",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "immunoglobulin G (IgG) > 3.5 g/dl",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "decrease in uninvolved immunoglobulins: immunoglobulin A (IgA) > 2 g/dl",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "no prior therapy",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "life expectancy greater than 3 months",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "eastern cooperative oncology group (ecog) performance status <3",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "ability to understand and the willingness to sign a written informed consent document",
      "label": "met",
      "evidence": "patient text"
    }
  ],
  "exclusion": [
    {
      "criterion": "pregnant women",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "patients may not be receiving any other investigational agents",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "history of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib, melphalan, or other agents used in the study",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy. therefore, hiv-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with bortezomib or other agents administered during the study",
      "label": "not_met",
      "evidence": "none"
    }
  ],
  "notes": "Patient has multiple myeloma, recurrent disease, and systemic amyloidosis. She is on hemodialysis for ESRD and was recently treated with pamidronate, calcitonin, and dialysis.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT00734149",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}